# Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa

> **NCT05392751** · PHASE1,PHASE2 · TERMINATED · sponsor: **Endogena Therapeutics, Inc** · enrollment: 14 (actual)

## Conditions studied

- Retinitis Pigmentosa
- Retinitis Pigmentosa Syndrome

## Interventions

- **DRUG:** EA-2353

## Key facts

- **NCT ID:** NCT05392751
- **Lead sponsor:** Endogena Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-02
- **Primary completion:** 2024-04-24
- **Final completion:** 2024-04-24
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Study terminated by the Sponsor. All study participants completed at least 12 months of safety follow-up instead of 24 mo. The reason for earlier termination was due to a corporate decision; not any safety concerns of EA-2353.
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05392751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05392751, "Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05392751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*